Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL

被引：0
|
作者：
Shanafelt, Tait D. [1 ]
Lanasa, Mark C. [2 ]
Zent, Clive S. [1 ]
Leis, Jose F. [3 ]
Call, Timothy G. [1 ]
LaPlant, Betsy R.
Tun, Han [4 ]
Bowen, Deborah A. [1 ]
Jelinek, Diane F. [5 ]
Hanson, Curtis A. [6 ]
Kay, Neil [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Mayo Clin Arizona, Div Hematol & Med Oncol, Scottsdale, AZ USA
[4] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA
[5] Mayo Clin, Dept Immunol, Rochester, MN USA
[6] Mayo Clin, Div Hematopathol, Dept Lab Med, Rochester, MN USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1665 / 1666
页数：2
相关论文
共 50 条
  • [31] A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL
    Wierda, William G.
    Balakrishnan, Kumudha
    Ferrajoli, Alessandra
    Kadie, Tapan
    Cortes, Jorge E.
    O'Brien, Susan
    Burger, Jan A.
    Tambaro, Francesco Paolo
    Jalayer, Annette
    Lemer, Susan
    Keating, Michael J.
    Gandhi, Varsha
    BLOOD, 2011, 118 (21) : 1667 - 1667
  • [32] Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial
    Strati, Paolo
    Lanasa, Mark
    Call, Timothy G.
    Leis, Jose F.
    Brander, Danielle M.
    LaPlant, Betsy R.
    Pettinger, Adam M.
    Ding, Wei
    Parikh, Sameer A.
    Hanson, Curtis A.
    Chanan-Khan, Asher A.
    Bowen, Deborah A.
    Conte, Michael
    Kay, Neil E.
    Shanafelt, Tait D.
    LANCET HAEMATOLOGY, 2016, 3 (09): : E407 - E414
  • [33] FLUDARABINE IN UNTREATED AND PREVIOUSLY TREATED B-CLL PATIENTS - A REPORT ON EFFICIENCY AND TOXICITY
    SPRIANO, M
    CLAVIO, M
    CARRARA, P
    CANEPA, L
    MIGLINO, M
    PIERRI, I
    CELESTI, L
    ROSSI, E
    VIMERCATI, R
    BRUNI, R
    SANTINI, G
    GATTI, AM
    STURA, P
    GHIO, R
    PATRONE, F
    DAMASIO, E
    GOBBI, M
    HAEMATOLOGICA, 1994, 79 (03) : 218 - 224
  • [34] Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
    Stilgenbauer, Stephan
    Leblond, Veronique
    Foa, Robin
    Boettcher, Sebastian
    Ilhan, Osman
    Knauf, Wolfgang
    Mikuskova, Eva
    Renner, Christoph
    Tausch, Eugen
    Woszczyk, Dariusz
    Gresko, Ekaterina
    Lundberg, Linda
    Moore, Tom
    Morris, Thea
    Robson, Susan
    Bosch, Francesc
    LEUKEMIA, 2018, 32 (08) : 1778 - 1786
  • [35] Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
    Stephan Stilgenbauer
    Veronique Leblond
    Robin Foà
    Sebastian Böttcher
    Osman Ilhan
    Wolfgang Knauf
    Eva Mikuskova
    Christoph Renner
    Eugen Tausch
    Dariusz Woszczyk
    Ekaterina Gresko
    Linda Lundberg
    Tom Moore
    Thea Morris
    Susan Robson
    Francesc Bosch
    Leukemia, 2018, 32 : 1778 - 1786
  • [36] Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial
    Pinilla-Ibarz, Javier
    Chavez, Julio C.
    Turba, Elyce
    Nodzon, Lisa
    Rock-Klotz, Jennifer
    Dalia, Samir
    Komrokji, Rami S.
    Locke, Frederick L.
    Kharfan-Dabaja, Mohamed A.
    Bello, Celeste M.
    BLOOD, 2015, 126 (23)
  • [37] Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL
    Hillmen, Peter
    Janssens, Ann
    Babu, K. Govind
    Kloczko, Janusz
    Grosicki, Sebastian
    Manson, Stephanie
    McKeown, Astrid
    Gupta, Ira
    Chang, Chai-Ni
    Offner, Fritz
    ACTA ONCOLOGICA, 2016, 55 (9-10) : 1115 - 1120
  • [38] Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)
    Blum, Kristie A.
    Polley, Mei-Yin
    Jung, Sin-Ho
    Dockter, Travis J.
    Anderson, Sarah
    Hsi, Eric D.
    Wagner-Johnston, Nina
    Christian, Beth
    Atkins, Jim
    Cheson, Bruce D.
    Leonard, John P.
    Bartlett, Nancy L.
    CANCER, 2019, 125 (19) : 3378 - 3389
  • [39] Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib
    Ahn, Inhye E.
    Jerussi, Theresa
    Farooqui, Mohammed
    Tian, Xin
    Wiestner, Adrian
    Gea-Banacloche, Juan
    BLOOD, 2016, 128 (15) : 1940 - 1943
  • [40] A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)
    Chen, Christine I.
    Paul, Harminder
    Snitzler, Susi
    Kakar, Sumeet
    Le, Lisa W.
    Wei, Ellen N.
    Lau, Anthea
    Johnston, James B.
    Gibson, Spencer B.
    Queau, Michelle
    Spaner, David
    Croucher, Danielle
    Sherry, Barbara
    Trudel, Suzanne
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 980 - 989
12345